Table 1. Summary characteristics of patient cohort.
| |
Model data set |
Test data set |
|---|---|---|
| No. patients | No. patients | |
| Age (IQR): years |
31.2 (26.1–36.1) |
30.9 (26.1–35.6) |
| Interval between evacuation and first MTX dosing (IQR): months |
1.9 (1.3–2.9) |
1.9 (1.4–3.2)a |
| Choriocarcinoma (%) |
19 (4.5) |
18 (4.7) |
|
WHO–FIGO sore | ||
| 0 (%) | 37 (8.9) | 33 (8.6) |
| 1 (%) | 76 (18.2) | 73 (19.1) |
| 2 (%) | 95 (22.7) | 82 (21.5) |
| 3 (%) | 105 (25.1) | 108 (28.3) |
| 4 (%) | 70 (16.7) | 60 (15.7) |
| 5 (%) | 28 (6.7) | 18 (4.7) |
| 6 (%) |
7 (1.7) |
8 (2.1) |
| Number of MTX received: median (IQR) (range) |
6 (4–7) (3–14) |
6 (4–7) (3–12) |
|
Response to MTX | ||
| Sensitive (%) | 223 (53.3) | 238 (62.3) |
| Resistant (%) |
195 (46.7) |
144 (37.7) |
| Total (n=800 patients) | 418 | 382 |
Abbreviations: IQR=interquartile range; MTX=methotrexate; WHO–FIGO=WHO–International Federation of Gynecology and Obstetrics.
a
Unknown for one patient.